Novavax Inc Market Cap ($1.31 Billion)
Market Cap & Net Worth: Novavax Inc (NVAX)
Novavax Inc market cap. Novavax Inc (NASDAQ:NVAX) has a market capitalization of $1.31 Billion ($1.31 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7560 globally and #2296 in its home market, demonstrating a 6.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novavax Inc's stock price $10.65 by its total outstanding shares 164945726 (164.95 Million). Also see Novavax Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Novavax Inc Market Cap History (2015–2026)
Novavax Inc market cap history from 2015 to 2026. Data shows change from $27.68 Billion to $1.76 Billion (-21.32% CAGR). Check Novavax Inc stock quote for real-time trading data and today's change.
Index Memberships
Novavax Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.15 Trillion | 0.11% | #21 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.05% | #222 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #847 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.07% | #129 of 263 |
Weight: Novavax Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novavax Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novavax Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Novavax Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.99x
Novavax Inc's market cap is 0.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.52x
Novavax Inc's market cap is 2.52 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.16 Billion | $15.35 Million | -$279.97 Million | 270.74x | N/A |
| 2017 | $4.09 Billion | $31.18 Million | -$183.77 Million | 131.21x | N/A |
| 2018 | $6.07 Billion | $34.29 Million | -$184.75 Million | 177.03x | N/A |
| 2019 | $656.48 Million | $18.66 Million | -$130.10 Million | 35.18x | N/A |
| 2020 | $18.39 Billion | $475.60 Million | -$427.50 Million | 38.67x | N/A |
| 2021 | $23.60 Billion | $1.15 Billion | -$1.74 Billion | 20.59x | N/A |
| 2022 | $1.70 Billion | $1.60 Billion | -$657.94 Million | 1.06x | N/A |
| 2023 | $791.74 Million | $556.38 Million | -$545.06 Million | 1.42x | N/A |
| 2024 | $1.33 Billion | $682.16 Million | -$187.50 Million | 1.94x | N/A |
| 2025 | $1.11 Billion | $1.12 Billion | $440.30 Million | 0.99x | 2.52x |
Competitor Companies of NVAX by Market Capitalization
Companies near Novavax Inc in the global market cap rankings as of November 5, 2026. Also see NVAX asset base for a full breakdown of the balance sheet.
Key companies related to Novavax Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Novavax Inc (2015–2026)
Market capitalization of Novavax Inc from 2015 to today. Between 2015 and today, Novavax Inc's market cap moved from $27.68 Billion to $ 1.76 Billion, with a yearly change of -21.32%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.76 Billion | +58.48% |
| 2025 | $1.11 Billion | -16.42% |
| 2024 | $1.33 Billion | +67.50% |
| 2023 | $791.74 Million | -53.31% |
| 2022 | $1.70 Billion | -92.81% |
| 2021 | $23.60 Billion | +28.30% |
| 2020 | $18.39 Billion | +2701.76% |
| 2019 | $656.48 Million | -89.18% |
| 2018 | $6.07 Billion | +48.39% |
| 2017 | $4.09 Billion | -1.59% |
| 2016 | $4.16 Billion | -84.98% |
| 2015 | $27.68 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Novavax Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.31 Billion USD |
| MoneyControl | $1.31 Billion USD |
| MarketWatch | $1.31 Billion USD |
| marketcap.company | $1.31 Billion USD |
| Reuters | $1.31 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more